SILO PHARMA, INC. Net Income (Loss) Available to Common Stockholders, Diluted
SILO PHARMA, INC. (SILO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$3.91 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2023-03-24
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was -$1.66M.
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-09-30 was -$983.25K, a 115.40% decline year-over-year.
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-06-30 was -$658.40K.
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2022-03-31 was -$604.07K.
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$3.91M, a 256.36% decline from fiscal 2021.
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2021 was $2.50M.
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$3.11M.
- SILO PHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2019 was -$1.01M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$2.65M derived: sum of 2 quarters · filed 2023-03-24 | -$3.30M derived: sum of 3 quarters · filed 2023-03-24 | -$3.91M 10-K · filed 2023-03-24 |
| 2022-09-30 | -$983.25K 10-Q · filed 2022-11-10 | -$1.64M derived: sum of 2 quarters · filed 2022-11-10 | -$2.25M 10-Q · filed 2022-11-10 | -$3.33M derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-06-30 | -$658.40K 10-Q · filed 2022-08-01 | -$1.26M 10-Q · filed 2022-08-01 | -$2.35M derived: sum of 3 quarters · filed 2023-03-24 | $4.03M derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-03-31 | -$604.07K 10-Q · filed 2022-05-13 | -$1.69M derived: sum of 2 quarters · filed 2023-03-24 | $4.69M derived: sum of 3 quarters · filed 2023-03-24 | $4.23M derived: sum of 4 quarters · filed 2023-03-24 |
| 2021-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $5.30M derived: sum of 2 quarters · filed 2023-03-24 | $4.83M derived: sum of 3 quarters · filed 2023-03-24 | $2.50M 10-K · filed 2023-03-24 |
| 2021-09-30 | $6.39M 10-Q · filed 2022-11-10 | $5.92M derived: sum of 2 quarters · filed 2022-11-10 | $3.59M 10-Q · filed 2022-11-10 | $2.80M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$461.99K 10-Q · filed 2022-08-01 | -$2.80M 10-Q · filed 2022-08-01 | -$3.59M derived: sum of 3 quarters · filed 2022-08-01 | -$4.22M derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | -$2.33M 10-Q · filed 2022-05-13 | -$3.12M derived: sum of 2 quarters · filed 2022-05-13 | -$3.76M derived: sum of 3 quarters · filed 2022-05-13 | -$5.20M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$789.81K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$1.42M derived: sum of 2 quarters · filed 2022-03-28 | -$2.87M derived: sum of 3 quarters · filed 2022-03-28 | -$3.11M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$633.79K 10-Q · filed 2021-11-10 | -$2.08M derived: sum of 2 quarters · filed 2021-11-10 | -$2.32M 10-Q · filed 2021-11-10 | -$2.70M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$1.44M 10-Q · filed 2021-08-13 | -$1.68M 10-Q · filed 2021-08-13 | -$2.06M derived: sum of 3 quarters · filed 2021-08-13 | -$2.33M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | -$238.88K 10-Q · filed 2021-05-17 | -$620.96K derived: sum of 2 quarters · filed 2021-05-17 | -$886.44K derived: sum of 3 quarters · filed 2021-05-17 | -$1.13M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$382.08K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-17 | -$647.56K derived: sum of 2 quarters · filed 2021-05-17 | -$889.77K derived: sum of 3 quarters · filed 2021-05-17 | -$1.01M 10-K/A · filed 2021-05-17 |
| 2019-09-30 | -$265.48K 10-Q · filed 2020-11-05 | -$507.69K derived: sum of 2 quarters · filed 2020-11-05 | -$631.22K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$242.21K 10-Q · filed 2020-08-14 | -$365.73K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |